Missed rifampicin and isoniazid resistance by commercial molecular assays

Drug-resistant tuberculosis (TB) has poor outcomes unless resistance is detected early, ideally by commercially available molecular tests. We present a case of occult multidrug-resistant TB where both rifampicin and isoniazid resistance were missed by molecular testing and were only identified by ph...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	South African medical journal 2024-07, Vol.114 (7), p.e1779
Hauptverfasser:	Richards, L, Ismail, F, Nel, J, Omar, S V
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antitubercular Agents - pharmacology Humans Isoniazid Male Microbial Sensitivity Tests Multidrug resistant TB Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - genetics Mycobacterium tuberculosis - isolation & purification Rifampin - pharmacology Rifampin - therapeutic use TB diagnostics Tuberculosis, Multidrug-Resistant - diagnosis Tuberculosis, Multidrug-Resistant - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Drug-resistant tuberculosis (TB) has poor outcomes unless resistance is detected early, ideally by commercially available molecular tests. We present a case of occult multidrug-resistant TB where both rifampicin and isoniazid resistance were missed by molecular testing and were only identified by phenotypic testing.
ISSN:	0256-9574 2078-5135 2078-5135
DOI:	10.7196/SAMJ.2024.v114i17.1779